Basilea Shares Down on U.S. Setback

June 25, 2014 8:38 AM

5 0

ZURICH—Basilea Pharmaceutica AG said Wednesday the U.S. Food and Drug Administration requires more information about its ceftobiprole pneumonia treatment before it can be approved.

The FDA needs additional phase 3 data on the drug before it can be approved in the U.S., Basilea said in a statement.

Also read: EU fines 3 banks $520 million over market rigging

Read more

To category page

Loading...